Addex Therapeutics (ADXN) EBITDA (2017 - 2026)

Addex Therapeutics has disclosed EBITDA across 10 years of filings, most recently posting -$612741.3 for Q1 2026.

• In Q1 2026, EBITDA rose 9.13% year-over-year to -$612741.3; the TTM figure through Mar 2026 stood at -$3.3 million (up 39.56% YoY), while the FY2025 annual figure was -$3.4 million, down 8.39% from the prior year.
• EBITDA came in at -$612741.3 for Q1 2026 at Addex Therapeutics, up from -$974990.3 in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$397867.8 in Q1 2023 to a low of -$21.3 million in Q4 2022.
• Average EBITDA over 5 years is -$3.1 million, with a median of -$902797.7 recorded in 2024.
• Year-over-year, EBITDA surged 94.02% in 2023 and slumped 126.91% in 2024.
• Over 5 years, EBITDA stood at -$21.3 million in 2022, then surged by 88.13% to -$2.5 million in 2023, then decreased by 24.37% to -$3.1 million in 2024, then soared by 69.0% to -$974990.3 in 2025, then jumped by 37.15% to -$612741.3 in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$612741.3 in Q1 2026, -$974990.3 in Q4 2025, and -$870295.0 in Q3 2025.